Abera Bioscience AB

Abera Bioscience has a total equity of $19.29 million and total liabilities of $9.28 million, resulting in a debt-to-equity ratio of 0.0, indicating no leverage. The company's current ratio of 2.73 suggests it has sufficient short-term assets to cover its liabilities. However, the company reported negative operating and net income of $10.58 million and $10.45 million, respectively, and negative operating and free cash flows of $3.26 million and $10.69 million, indicating ongoing cash burn. The company's return on equity (ROE) is -54.2%, and return on assets (ROA) is -36.6%, both significantly below the industry median for biotechnology firms, which typically report positive ROE and ROA in the 10-20% range. These metrics suggest poor capital efficiency and operational performance relative to peers. Abera Bioscience's revenue is not disclosed in the input data, and no segment or geographic breakdown is provided. The company's business is described as being "located around the Nordic market," but no specific revenue concentration or geographic exposure is quantified. The lack of segment data limits the ability to assess diversification or concentration risk. The company's growth trajectory is not quantified in the input data, and no revenue history is provided. The outlook for the current and next fiscal years is not specified, but the ongoing negative cash flows and lack of profitability suggest a challenging path to growth. The company's strategy appears to rely on licensing its vaccine candidates, which is a high-risk, high-reward approach with uncertain timing and outcomes. The risk assessment indicates low dilution risk, with no near-term pressure for additional equity issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's reliance on external financing and the absence of profitability increase the risk of liquidity constraints in the future. No recent events, such as filings or transcripts, are provided in the input data to inform the company's current status or strategic direction. The lack of recent disclosures limits the ability to assess management's execution or external developments affecting the company.